In the fast-moving world of pharmaceuticals, time is everything. But speed should never come at the cost of quality. Now, you can have both. Introducing Instacoat 4G®, the revolutionary film coating solution with high solids content (35 per cent) that empowers you to work faster, smarter, and greener - without compromising on the excellence your products deserve.
Why to Choose Instacoat 4G®?
Instacoat 4G® is an advanced Polyvinyl Alcohol (PVA)based immediate-release film coating ready-mix that represents a leap forward in coating technology. As a fourth-generation product, it is the result of years of rigorous research and development, building on previous innovations to meet the ever-evolving demands of pharma manufacturing. Offering 35-40 per cent solids concentration the highest in the industry - it delivers unmatched reconstitution capability for faster preparation and higher operational efficiency. This groundbreaking feature sets a new industry standard, driving faster, more consistent coating performance.
This story is from the December 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
CILICANT is changing the way we think about active packaging
Team CILICANT shared insights into their journey of innovation, customer-centric solutions, and their ambitious plans for global expansion. In this engaging dialogue, the team also shed light on their unique value proposition, recent achievements, and strategies for adapting to a rapidly evolving pharma landscape, in an exclusive conversation with Express Pharma
KPMG 2024 Life Sciences CEO Outlook
This recent KPMG report explores the perspectives and priorities of life sciences CEOs amid economic and geopolitical uncertainty, focusing on growth strategies, digital transformation, ESG goals, and workforce challenges. Excerpts from the report
Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends
Industry experts highlight the evolving dynamics, regulatory needs, and personalised solutions driving the nutra market ahead of 2025
We aim to strengthen our presence in Asian and MENA regions, with particular emphasis on India
Matthias Poslovski, Chief Sales Officer, Optima Pharma, speaks on the company's evolution and shares insights on emerging trends like personalised medicine, digitalisation, and Al-driven technologies, while outlining his company's strategies for market expansion, particularly in Asia and MENA, with a focus on the Indian pharma sector, in an exclusive interaction with Lakshmipriya Nair
Sustaining excellence: The evolving role of quality in pharma
In the ever-evolving landscape of the pharma industry, the pursuit of quality remains a cornerstone of success. As stringent regulatory frameworks, rising patient expectations, and the increasing pace of innovation, transforms the pharma industry, the definition of quality is also evolving. From ensuring compliance with global standards to embracing cutting-edge technologies like Al-driven quality control, the industry is navigating a paradigm shift in how it approaches product integrity, safety, and efficacy. In this New Year issue, pharma experts explore how crucial it is to foster a culture of quality across organisations and deliver better healthcare outcomes
Revolutionising pharma the adaptive way
Adaptive manufacturing offers better performance, efficient management of diverse products, a reduced machine footprint, faster batch changes, and enhanced operational sustainability
Trends 2025: Redefining the pharma supply chain
Saurabh Gupta, Global Head of Supply Chain, Lupin highlights trends such as Al integration, digitalisation and sustainability that are shaping a future-ready supply chain
Growth mantras for 2025: Innovation, Partnerships, Sustainability
Innovation, synergy, and sustainability are shaping the trajectory of India's pharma sector, unlocking new frontiers of growth, inform industry stakeholders
Will Epygen's biosimilars bets pay off?
Debayan Ghosh, founder, Epygen Group, has ambitious plans to snag a slice of the booming $70 billion global biosimilar pie. In a conversation with Viveka Roychowdhury, he analyses the journey so far, spanning pandemic preparedness projects like protein-based vaccines, building up pipeline revenue streams in diabetes, oncology, immunology and cardiovascular biosimilars, and his strategies to scale up and expand to other therapeutics like anti-obesity drugs
Innovation, partnerships and best practices: Priorities for biopharma in 2025
Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth
